奧園美谷(000615.SZ):與源美生物、美樂生物及肌源醫藥等簽署股權投資(轉讓)意向協議書
格隆匯6月3日丨奧園美谷(000615.SZ)公佈,公司全資子公司廣州奧美產業研究有限公司於2021年6月3日與源美生物技術開發(大連)有限公司、大連美樂生物技術開發有限公司、大連肌源醫藥科技有限公司、韓廣權、韓廣文、陳豔秋、張文博、陳文超簽署了《股權投資(轉讓)意向協議書》,就股權投資(轉讓)事項進行約定。
其中包括,肌源醫藥與源美生物、美樂生物合稱“標的公司”,主要從事化粧品研發、生產和銷售;醫療器械的研發;消字號產品及器械的研發、生產和銷售(“項目業務”);
乙方源美生物、美樂生物、肌源醫藥希望與甲方廣州奧美產業研究有限公司合作共同致力於拓展標的公司項目業務;
甲方願意根據意向書約定的條款與乙方簽署正式投資協議,並根據正式投資協議的約定投入資金,與乙方合作,共同致力於項目業務的開發。
甲方或其指定相關公司擬以發起設立的併購基金對標的公司進行併購,按照市場公允價格和當前產業板塊估值,採用受讓標的公司創始人直接或間接持有的股權的方式收購標的公司股權比例51%-70%;
標的公司創始人擬認購併購基金的一定份額;甲方指定的機構擔任併購基金管理人,甲方在併購基金中擔任劣後級合夥人,標的公司創始人擔任優先級合夥人;
此次投資估值是在基準日為2021年6月30日合併審計財務數據的基礎上,創始人承諾標的公司2021年-2023年三年平均主營業務收入不低於1億元,淨利潤不低於人民幣3000萬元以上作出。若三年平均主營業務收入及淨利潤低於前述承諾,則甲方有權單方決定終止本次投資。對標的公司的估值以最終投資協議為準;
此次簽署的《股權投資(轉讓)意向協議書》標誌着各方的戰略合作取得階段性成果,為簽訂正式協議奠定基礎。本意向協議的簽署對公司本年度經營業績不構成重大影響,不影響公司的業務獨立性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.